---
title: "REPL: FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291144115.md"
description: "FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.Original document: Replimune Group, Inc. [REPL] SEC 8-K Current Report — Jul. 9 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-29T12:14:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291144115.md)
  - [en](https://longbridge.com/en/news/291144115.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291144115.md)
generator: "portal-rs"
---

# REPL: FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical results

FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.

Original document: Replimune Group, Inc. \[REPL\] SEC 8-K Current Report — Jul. 9 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune RP1 melanoma BLA wins favorable 10-3 FDA advisory panel vote on IGNYTE efficacy data](https://longbridge.com/en/news/294422729.md)
- [Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million](https://longbridge.com/en/news/295931365.md)
- [ENGN: Pivotal data and BLA filing for detalimogene on track, supported by strong cash reserves](https://longbridge.com/en/news/298312691.md)
- [enGene Reports Q3 2026: $266.3M Cash, $32.5M Net Loss; BLA Filing Planned 4Q26](https://longbridge.com/en/news/298313337.md)
- [CADL: BLA submission for aglatimogen in prostate cancer is planned by year-end, with key data updates ahead](https://longbridge.com/en/news/298642995.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**